MAIA Announces First Patient Dosed in Epithelial Carcinoma Study
MAIA Biotechnology initiated a Phase 1b clinical study for enhanced TRIDENT-CKD therapy to treat epithelial carcinomas. The event represents a significant operational milestone indicating progress in clinical development.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed